|Bid||90.16 x 900|
|Ask||90.61 x 800|
|Day's Range||89.61 - 91.06|
|52 Week Range||66.23 - 98.11|
|Beta (5Y Monthly)||1.09|
|PE Ratio (TTM)||66.77|
|Earnings Date||Jul 21, 2021 - Jul 26, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||98.85|
Edwards Lifesciences (NYSE: EW) today announced the results of a real-world study comparing outcomes for patients with bicuspid aortic stenosis (AS) who were treated with SAPIEN 3 and SAPIEN 3 Ultra Transcatheter Aortic Valve Replacement (TAVR) and at low risk of death from surgery. The data show excellent outcomes at one year, with low rates of death and stroke, and no significant differences in the primary outcomes compared with the overall cohort, or those with tricuspid aortic valve disease.
Edwards Lifesciences (NYSE: EW) today announced that clinical results from the company's transcatheter mitral and tricuspid programs were presented as part of the late-breaking clinical trials at EuroPCR 2021, demonstrating positive outcomes for patients impacted by mitral or tricuspid heart valve disease.
Sands Capital Management ups stakes in tech picks, trims Adobe